B

BioInvent International AB
STO:BINV

Watchlist Manager
BioInvent International AB
STO:BINV
Watchlist
Price: 28.45 SEK 2.34% Market Closed
Market Cap: 1.9B SEK

EV/EBITDA
Enterprise Value to EBITDA

-5.7
Current
-4.2
Median
6.3
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-5.7
=
Enterprise Value
1.9B SEK
/
EBITDA
-327.8m SEK
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
SE
B
BioInvent International AB
STO:BINV
Average EV/EBITDA: 40
Negative Multiple: -5.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 499.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -577.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
NL
argenx SE
XBRU:ARGX
59.4
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
160.9
N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
2.1
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A